COVID-19: TIF Releases Position Statement on the Inclusion of Thalassaemia & SCD Patients in the High-Risk Population

The SARS-CoV-2 infection presents particular challenges and great risks to patients with thalassaemia and sickle cell disease (SCD) and, if their appropriate clinical management as described in International Guidelines is not safeguarded in the context of national policies developed for fighting COVID-19, their health and quality of life will be tragically impacted while in addition and considering their worldwide occurrence, an immense strain will be posed to the health care and public health system of every country.

Therefore, TIF encourages National Health Authorities of every country across every Region of the world, in the context of their national fight against the COVID-19 pandemic, to promote and adopt the following series of policies in relation to the protection of the health and lives of individuals with haemoglobin disorders.

Read the TIF Position Statement HERE